Hyloris On Track To Meet 2024 Target During Half-Year Update
Company Aims To Expand Its Portfolio To 30 Products By 2024
Executive Summary
Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.
You may also be interested in...
Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray
Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024.
FDA Asks Hyloris For More Data On Maxigesic IV
Hyloris has received a complete response letter from the US FDA asking for more information on its 505(b)(2) hybrid application for its Maxigesic IV intravenous analgesic for treating post-operative pain.
Hyloris Raises €15m In Private Equity Offering
Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.